Enhanced Access to Affordable Medicines Act of 2022
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Mar 8, 2022)
Enhanced Access to Affordable Medicines Act of 2022
This bill specifies that the Food and Drug Administration may approve generic drugs with different labels than the brand-name versions if, among other requirements, the brand-name drug is subject to an active patent or exclusivity period and a revised label for the brand-name drug is approved within 90 days (rather than 60 days) of the expiration of the patent or exclusivity period.
What just happenedMar 9, 2022
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseMar 8, 2022
- Mar 9, 2022Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Mar 8, 2022IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Mar 8, 2022IntroReferralIntro-H
Introduced in House
- Mar 8, 2022IntroReferral1000
Introduced in House